Other
Illumisoft Lighting Corp. Provides Corporate Update Following Commencement of Trading
Illumisoft Lights Path to Commercialization Amidst Regulatory Tailwinds and Debt Maturity Risks
Executive Summary
Corporate Update Post-Listing
- Illumisoft Lighting Corp. (TSXV: UVC) provided a comprehensive update following its TSX Venture Exchange listing commencement on April 23, 2026.
- The company highlighted clinical efficacy data for SaniLume upper room UV disinfection devices from the University of Leeds testing.
- Regulatory tailwinds were emphasized, citing new Canadian healthcare standards (CSA Z8000:24 and CSA Z317.12:25) mandating automated disinfection technologies in architectural design.
- Development of SaniLux, a patented Far UVC technology for occupied spaces, was announced alongside commercialization plans.
Material Impact
Positive Drivers
- Regulatory Mandates: The identification of upper room GUV systems as essential in CSA Z8000:24 creates a potential long-term revenue floor for the SaniLume product line, reducing reliance on voluntary adoption.
- Clinical Validation: Independent testing showing >99% inactivation of key pathogens (Pseudomonas aeruginosa, Staphylococcus aureus) provides tangible proof of concept for investors and customers.
- Strategic Alignment: The involvement of Resilience Reserve adds credibility to the management team's vision, particularly given Anderson's background in media/tech innovation.
UVC · Price
Company Overview
Corporate Structure
- Former Name: Gstaad Capital Corp.
- Current Name: Illumisoft Lighting Corp. (TSXV: UVC).
- Transaction Type: Qualifying Transaction (QT) with Claranova Technologies Inc., completed April 21, 2026.
- Listing Date: April 23, 2026 on TSX Venture Exchange.